In this regard a double-blind clinical trial involving 70 patients with T2DM revealed that anakinra administration improves beta-cell secretory function: moreover, the beneficial effects on insulin production and systemic proinflammatory parameters were prolonged over time, even after anakinra cessation [182, 183]. The gene discussed is INS; the disease is type 2 diabetes mellitus.